AWM
RETA

Avior Wealth Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Avior Wealth Management’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,030
Closed -$160K – 1040
2020
Q2 		$160K Sell
1,030
-130
-11% -$19.8K 0.03% 395
2020
Q1 		$167K Buy
1,160
+550
+90% +$106K 0.03% 366
2019
Q4 		$124K Buy
+610
New +$111K 0.02% 409

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Avior Wealth Management's RETA Position: Q3 2020 in Review

Avior Wealth Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2020, closing a stake of 1,030 shares — an estimated $160K sold.

Avior Wealth Management first reported a position in RETA in Q4 2019 and held it in 3 quarters. The position peaked at $167K in Q1 2020. 186 funds tracked by Wall St. Rank hold RETA as of Q3 2020.

  • Avior Wealth Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2020 after selling out during the quarter.
  • Avior Wealth Management sold 1,030 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2020, an estimated $160K.
  • Avior Wealth Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 3 quarters.
  • Avior Wealth Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $167K in Q1 2020.
  • 186 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2020.

Based on Avior Wealth Management's 13F filing for Q3 2020, filed 20 Oct 2020.